Literature DB >> 24458973

3-substituted indazoles as configurationally locked 4EGI-1 mimetics and inhibitors of the eIF4E/eIF4G interaction.

Revital Yefidoff-Freedman1, Ting Chen, Rupam Sahoo, Limo Chen, Gerhard Wagner, Jose A Halperin, Bertal H Aktas, Michael Chorev.   

Abstract

4EGI-1, the prototypic inhibitor of eIF4E/eIF4G interaction, was identified in a high-throughput screening of small-molecule libraries with the aid of a fluorescence polarization assay that measures inhibition of binding of an eIF4G-derived peptide to recombinant eIF4E. As such, the molecular probe 4EGI-1 has potential for the study of molecular mechanisms involved in human disorders characterized by loss of physiological restraints on translation initiation. A hit-to-lead optimization campaign was carried out to overcome the configurational instability in 4EGI-1, which stems from the E-to-Z isomerization of the hydrazone function. We identified compound 1 a, in which the labile hydrazone was incorporated into a rigid indazole scaffold, as a promising rigidified 4EGI-1 mimetic lead. In a structure-activity relationship study directed towards probing the structural latitude of this new chemotype as an inhibitor of eIF4E/eIF4G interaction and translation initiation we identified 1 d, an indazole-based 4EGI-1 mimetic, as a new and improved lead inhibitor of eIF4E/eIF4G interaction and a promising molecular probe candidate for elucidation of the role of cap-dependent translation initiation in a host of pathophysiological states.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  eIF4E/eIF4G interaction; inhibitors; molecular probes; protein-protein interactions; translation initiation

Mesh:

Substances:

Year:  2014        PMID: 24458973      PMCID: PMC4259117          DOI: 10.1002/cbic.201300723

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  60 in total

1.  Discovery of TRPV1 antagonist ABT-116.

Authors:  Brian S Brown; Ryan Keddy; Richard J Perner; Stanley DiDomenico; John R Koenig; Tammie K Jinkerson; Steven M Hannick; Heath A McDonald; Bruce R Bianchi; Prisca Honore; Pamela S Puttfarcken; Robert B Moreland; Kennan C Marsh; Connie R Faltynek; Chih-Hung Lee
Journal:  Bioorg Med Chem Lett       Date:  2010-04-14       Impact factor: 2.823

Review 2.  Small-molecule protein-protein interaction inhibitors: therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations.

Authors:  Peter Buchwald
Journal:  IUBMB Life       Date:  2010-10       Impact factor: 3.885

Review 3.  Fine-tuning multiprotein complexes using small molecules.

Authors:  Andrea D Thompson; Amanda Dugan; Jason E Gestwicki; Anna K Mapp
Journal:  ACS Chem Biol       Date:  2012-07-23       Impact factor: 5.100

Review 4.  Targeting protein-protein interactions with small molecules: challenges and perspectives for computational binding epitope detection and ligand finding.

Authors:  Domingo González-Ruiz; Holger Gohlke
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

5.  Pten deletion in adult hippocampal neural stem/progenitor cells causes cellular abnormalities and alters neurogenesis.

Authors:  Anahita Amiri; Woosung Cho; Jing Zhou; Shari G Birnbaum; Christopher M Sinton; Renée M McKay; Luis F Parada
Journal:  J Neurosci       Date:  2012-04-25       Impact factor: 6.167

6.  Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1.

Authors:  H Aktas; H Cai; G M Cooper
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

7.  The TSC1 and TSC2 tumor suppressors are required for proper ER stress response and protect cells from ER stress-induced apoptosis.

Authors:  Y J Kang; M-K Lu; K-L Guan
Journal:  Cell Death Differ       Date:  2010-07-09       Impact factor: 15.828

8.  The autistic neuron: troubled translation?

Authors:  Raymond J Kelleher; Mark F Bear
Journal:  Cell       Date:  2008-10-31       Impact factor: 41.582

9.  The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP.

Authors:  Ilaria Napoli; Valentina Mercaldo; Pietro Pilo Boyl; Boris Eleuteri; Francesca Zalfa; Silvia De Rubeis; Daniele Di Marino; Evita Mohr; Marzia Massimi; Mattia Falconi; Walter Witke; Mauro Costa-Mattioli; Nahum Sonenberg; Tilmann Achsel; Claudia Bagni
Journal:  Cell       Date:  2008-09-19       Impact factor: 41.582

10.  Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders.

Authors:  Brian J O'Roak; Laura Vives; Wenqing Fu; Jarrett D Egertson; Ian B Stanaway; Ian G Phelps; Gemma Carvill; Akash Kumar; Choli Lee; Katy Ankenman; Jeff Munson; Joseph B Hiatt; Emily H Turner; Roie Levy; Diana R O'Day; Niklas Krumm; Bradley P Coe; Beth K Martin; Elhanan Borenstein; Deborah A Nickerson; Heather C Mefford; Dan Doherty; Joshua M Akey; Raphael Bernier; Evan E Eichler; Jay Shendure
Journal:  Science       Date:  2012-11-15       Impact factor: 47.728

View more
  3 in total

1.  Consideration of Binding Kinetics in the Design of Stapled Peptide Mimics of the Disordered Proteins Eukaryotic Translation Initiation Factor 4E-Binding Protein 1 and Eukaryotic Translation Initiation Factor 4G.

Authors:  Erin E Gallagher; James M Song; Arya Menon; Lauren D Mishra; Alyah F Chmiel; Amanda L Garner
Journal:  J Med Chem       Date:  2019-05-09       Impact factor: 7.446

2.  High-Throughput Chemical Probing of Full-Length Protein-Protein Interactions.

Authors:  James M Song; Arya Menon; Dylan C Mitchell; Oleta T Johnson; Amanda L Garner
Journal:  ACS Comb Sci       Date:  2017-11-14       Impact factor: 3.784

Review 3.  Signalling to eIF4E in cancer.

Authors:  Nadeem Siddiqui; Nahum Sonenberg
Journal:  Biochem Soc Trans       Date:  2015-10       Impact factor: 5.407

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.